The paper presents the All-Russian consensus on the diagnosis and treatment of celiac disease in children and adults, which has been elaborated by leading experts, such as gastroenterologists and pediatricians of Russia on the basis of the existing Russian and international guidelines. The consensus approved at the 42nd Annual Scientific Session of the Central Research Institute of Gastroenterology on Principles of Evidence-Based Medicine into Clinical Practice (March 2-3, 2016). The consensus is intended for practitioners engaged in the management and treatment of patients with celiac disease. Evidence for the main provisions of the consensus was sought in electronic databases. In making recommendations, the main source was the publications included in the Cochrane Library, EMBASE, MEDLINE, and PubMed. The search depth was 10 years. Recommendations in the preliminary version were reviewed by independent experts. Voting was done by the Delphic polling system.
Обследовали 100 больных с ожирением. Регулируемое бандажирование желудка (РБЖ) было выполнено 20 пациентам, рукавная резекция желудка (РРЖ)-40 больным и гастрошунтирование (ГШ)-40 больным. Контрольную группу составили 10 практически здоровых людей. В сыворотке крови иммуноферментным методом определяли концентрацию витаминов В 1 , В 2 , В 5 , В 6 , В 9 , В 12 , С, D, ниацина, биотина и ретинол-связывающего белка (РСБ) до операции и через 1 год после хирургического лечения. Выявлено значительное снижение витаминов С, В 6 , В 5 , D и РСБ как до, так и после бариатрических операций (БО). Более половины больных, перенесших РРЖ, имели также исходное снижение уровня ниацина. Через год после проведения БО (РБЖ, РРЖ, ГШ) число больных с дефицитом этих витаминов сохранялось прежним либо увеличивалось. ГШ не оказало существенного влияния на концентрацию фолиевой кислоты, витаминов В 2 , В 12 , В 1 и биотина. У un-ta.-Bulletin of North Caucasian federal university. 2014;1(40):83-85. 4. Luk'janenko E. V. Ispol'zovanie NO-soderzhashhikh vozdushno-plazmennykh potokov v kompleksnom lechenii peritonita: avtoref. dis. … kand. med.nauk. M. 2006. 24 p. 5. Marakhonich L. A., Pekshev A. V. Infekcija v khirurgii-problema sovremennojj mediciny: sb. tez. 3-jj Vsearmejj. konf. s mezhdunar. uchastiem.-Infection in surgery-problem of modern medicine: collection of theses of third army conference.
Обследовали 100 больных с ожирением. Регулируемое бандажирование желудка (РБЖ) было выполнено 20 пациентам, рукавная резекция желудка (РРЖ)-40 больным и гастрошунтирование (ГШ)-40 больным. Контрольную группу составили 10 практически здоровых людей. В сыворотке крови иммуноферментным методом определяли концентрацию витаминов В 1 , В 2 , В 5 , В 6 , В 9 , В 12 , С, D, ниацина, биотина и ретинол-связывающего белка (РСБ) до операции и через 1 год после хирургического лечения. Выявлено значительное снижение витаминов С, В 6 , В 5 , D и РСБ как до, так и после бариатрических операций (БО). Более половины больных, перенесших РРЖ, имели также исходное снижение уровня ниацина. Через год после проведения БО (РБЖ, РРЖ, ГШ) число больных с дефицитом этих витаминов сохранялось прежним либо увеличивалось. ГШ не оказало существенного влияния на концентрацию фолиевой кислоты, витаминов В 2 , В 12 , В 1 и биотина. У un-ta.-Bulletin of North Caucasian federal university. 2014;1(40):83-85. 4. Luk'janenko E. V. Ispol'zovanie NO-soderzhashhikh vozdushno-plazmennykh potokov v kompleksnom lechenii peritonita: avtoref. dis. … kand. med.nauk. M. 2006. 24 p. 5. Marakhonich L. A., Pekshev A. V. Infekcija v khirurgii-problema sovremennojj mediciny: sb. tez. 3-jj Vsearmejj. konf. s mezhdunar. uchastiem.-Infection in surgery-problem of modern medicine: collection of theses of third army conference.
Aim. To define the frequency of adverse events and loss of the response in patients with ulcerative colitis (UC) and Crohns disease (CD), treated with original medicine infliximab (IFX) Remicaide and its biosimilars. Materials and methods. We included 154 patients with IBD: 78 UC patients (50.6%) и 76 CD patients (49.4%), treated with original medicine IFX Remicade and its biosimilars. In our study we did not include patients, who previously underwent induction treatment with IFX and its biosimilar. Results. Among 78 UC patients, IFX was cancelled in 25 (32.0%) patients and they were switched to the other anti-TNF inhibitor or medicine with the another mechanism of action; in patients group, treated with biosimilar 16 (20.5%) and 9 (11.5%) patients, who were interchanged biosimilar and/or original IFX. Among 76 CD patients IFX was cancelled in 20 (26.3%) patients: 11 (14.5%) patients in group, treated with similar trade name biosimilar, 8 (10.5%) patients, who were interchanged biosimilar and/or original IFX and 1 patient (1,3%), receiving original IFX. We found no difference in the secondary loss of response and adverse events in patients with CD and UC, switched from original IFX to biosimilar (p=0.6257 and p=0.6635, correspondingly). The frequency of the secondary loss of response or adverse events in patients with UC and CD, switched from original IFX to IFX biosimilar, was similar (p0.05). Conclusion. Approximately 30% of IBD patients, receiving IFX biosimilar, will be switched to the other anti-TNF therapy or medicine with the another mechanism of action because of secondary loss of response or adverse events.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.